Axium Pharmaceuticals said today that the FDA accepted its orphan designation request for the intranasal administration of lorazepam, Truveta, in the treatment of Lennox-Gastaut syndrome.
The High Point, N.C.-based company is developing a novel intranasal administration device for new formulations of existing drugs. Axium said the device is designed to bring about rapid onset of a therapeutic effect with minimal side effects, while boosting bio-availability.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA accepts Axium’s orphan designation request for intranasal Truveta appeared first on MassDevice.
from MassDevice http://ift.tt/2v8FSQ8
Cap comentari:
Publica un comentari a l'entrada